Food & Drug Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Food & Drug Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Fourth Military Medical University, Shaanxi
MAGE-n peptide could be immunotherapy target
September 24th, 2004
The MAGE-n peptide could be an immunotherapy target in hepatocellular carcinoma (HCC) patients. "MAGE-n is a new member of [the] MAGE gene family and has been demonstrated [to be] closely associated" with HCC, oncologists in China explained. In a study conducted by H.L. Dong and colleagues at the Fourth Military Medical University in Shaanxi, "MAGE-n-derived peptide-specific cytotoxic T lymphocytes (CTL) were induced from the peripheral blood mononuclear cells of healthy donors by multiple stimulations with HLA-A2-restricted MAGE-n peptide-pulsed T2 cells." "The induced CTLs exhibited specific lysis against T2 cells pulsed with...
Source: Food & Drug Law Weekly (2004-09-24)
|
